Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.
about
Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal OsteoporosisProteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applicationsAzanitrile Cathepsin K Inhibitors: Effects on Cell Toxicity, Osteoblast-Induced Mineralization and Osteoclast-Mediated Bone Resorption.Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal womenPotential role of odanacatib in the treatment of osteoporosis.Pit- and trench-forming osteoclasts: a distinction that mattersValue of rare low bone mass diseases for osteoporosis genetics.Understanding and targeting osteoclastic activity in prostate cancer bone metastases.The role of osteoclast differentiation and function in skeletal homeostasisEffects of odanacatib on bone matrix mineralization in rhesus monkeys are similar to those of alendronateHigh-throughput chinmedomics-based prediction of effective components and targets from herbal medicine AS1350.The bone resorption inhibitors odanacatib and alendronate affect post-osteoclastic events differently in ovariectomized rabbitsBone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.Inhibition of cathepsin K promotes osseointegration of titanium implants in ovariectomised ratsLong-term treatment with odanacatib maintains normal trabecular biomechanical properties in ovariectomized adult monkeys as demonstrated by micro-CT-based finite element analysis.Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target.Sclerosing bone dysplasias: leads toward novel osteoporosis treatments.Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cellsOdanacatib increases mineralized callus during fracture healing in a rabbit ulnar osteotomy model.Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.Theoretical studies on the interaction between the nitrile-based inhibitors and the catalytic triad of Cathepsin K.Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate.Tiludronate and clodronate do not affect bone structure or remodeling kinetics over a 60 day randomized trial.
P2860
Q27022580-FD842C54-1AB5-44CE-A579-4D6B88786AB7Q34476390-A2E2DBAD-B991-47D6-8168-9A40B638C6A3Q34484720-548B8756-F6C7-4AF7-A2F7-62B8E35D4E8DQ35033184-9954EF0B-B880-486E-9E4F-C5EBF1544F63Q35062434-E59B278B-F933-4F1C-92E7-A271A3D27ED5Q35109866-B87C0728-3DE5-4E36-8078-3A25651A32A3Q35589110-9073F91E-BE9D-4CD5-AD3C-DD1C946E8396Q36136239-499350B7-3A27-443F-A1AD-AB18D444AE9CQ36333959-2CFDFEA3-BAA3-4804-9CD5-21C0633F3856Q36440123-9EE1AAA3-EA9D-4D07-B74C-7798D89BAC6FQ36759374-F70DADA6-C42E-478E-A9A5-17BBBB0B75BBQ36941660-674C1B35-4C7B-4CEA-864C-4DCAA2045532Q37051593-F506637D-5937-4514-9DB4-D35326EA7AD0Q37464707-375DB822-C51D-418C-9A36-A75C59AE02A7Q37506421-85A01F2D-5ECA-4307-A7AD-B8A910EB128FQ37661855-BD9FFAA0-9F3E-49CA-A961-D707228A0778Q37708411-00A076AA-7D51-41EF-B12E-7798E05EC6C5Q37720677-0B096794-A2D7-4E42-A2D1-09A3F417595CQ38205860-9E152816-D35E-4D8D-8787-A6D0ADE1532FQ38221767-9F146D6B-0918-44A4-BD30-CEFD2143224DQ38582108-7C42D09C-6FD1-4DBB-92C1-8EDD162F16DAQ38784335-BB7102EB-A310-41C8-A26A-E2244D30A4B6Q41644080-ADD4C505-A752-43D7-A93E-2FCAC75A6D47Q46280547-AD351FB2-1F59-4209-936C-D8C72939B470Q53060269-064B15B8-A255-4F88-94F0-8B7CB78BE531Q53532908-7DBB6E6F-CB4D-4FD7-8130-EA3DD1CB3505Q53808499-EFCFF404-10D6-4F77-B769-9049A59E3F62Q55221571-D4CFE116-0A97-4FA1-B925-8AE7B1D2D95F
P2860
Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 May 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic inhibition of cath ...... le maintaining bone formation.
@en
Therapeutic inhibition of cath ...... le maintaining bone formation.
@nl
type
label
Therapeutic inhibition of cath ...... le maintaining bone formation.
@en
Therapeutic inhibition of cath ...... le maintaining bone formation.
@nl
prefLabel
Therapeutic inhibition of cath ...... le maintaining bone formation.
@en
Therapeutic inhibition of cath ...... le maintaining bone formation.
@nl
P2860
P356
P1433
P1476
Therapeutic inhibition of cath ...... le maintaining bone formation.
@en
P2093
Le T Duong
P2860
P2888
P356
10.1038/BONEKEY.2012.67
P577
2012-05-02T00:00:00Z